(Q81729508)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15882729%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

title

Androgen deprivation for minimal metastatic disease: threshold for achieving undetectable prostate-specific antigen (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15882729%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15882729%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

author name string

Kathleen Beekman

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15882729%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

Susan Slovin

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15882729%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

Glenn Heller

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15882729%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

Andrew Wilton

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15882729%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

Fernando Bianco

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15882729%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

Peter T Scardino

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15882729%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

Howard I Scher

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15882729%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

language of work or name

English

0 references

publication date

1 May 2005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15882729%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15882729%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

volume

65

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15882729%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

page(s)

947-952

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15882729%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15882729%20AND%20SRC:MED&resulttype=core&format=json

Cancer surveillance series: interpreting trends in prostate cancer--part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates.

11 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.12.012

American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.12.012

Improved Survival in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy and Goserelin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.12.012

Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.12.012

Intraoperative optimized inverse planning for prostate brachytherapy: early experience.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.12.012

6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.12.012

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.12.012

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.12.012

Carbohydrate vaccines in cancer: immunogenicity of a fully synthetic globo H hexasaccharide conjugate in man.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.12.012

Fully synthetic carbohydrate-based vaccines in biochemically relapsed prostate cancer: clinical trial results with alpha-N-acetylgalactosamine-O-serine/threonine conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.12.012

Vaccines as treatment strategies for relapsed prostate cancer: approaches for induction of immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.12.012

Nadir prostate-specific antigen best predicts the progression to androgen-independent prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.12.012

Nadir prostate-specific antigen as a predictor of progression to androgen-independent prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.12.012

Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.12.012

Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.12.012

Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.12.012

National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.12.012

Docetaxel followed by hormone therapy after failure of definitive treatments for clinically localized/locally advanced prostate cancer: preliminary results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.12.012

Docetaxel, estramustine, and short-term androgen withdrawal for patients with biochemical failure after definitive local therapy for prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.12.012

Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.12.012

10.1016/J.UROLOGY.2004.12.012

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15882729%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

1 reference